Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
Cancer · 2025
DOI: 10.1002/cncr.70132 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2025. Verfasst von Yamile Abuchard Anaya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immunology and Microbiology, Medicine, and Oncology Integrated Service Unit, School of Medicine, The University of Texas Rio Grand…. Hauptthemen laut MEDLINE: Proteolysis, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alzheimer's Association, NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Proteolysis‐targeting chimeras (PROTACs) have the potential to revolutionize cancer treatment by specifically targeting and degrading oncogenic proteins. Using the ubiquitin‐proteasome system, PROTACs allow the selective degradation of disease‐causing proteins, including those traditionally deemed “undruggable” by conventional small‐molecule inhibitors. By catalytically eliminating rather than inhibiting proteins, PROTACs provide sustained target suppression with lower doses and reduced toxicity. Their bifunctional design linking a protein of interest to an E3 ligase drives targeted ubiquitination and subsequent proteasomal degradation. Recent progress demonstrates promise in treating solid and hematologic malignancies, with several candidates advancing to clinical trials. This review provides a comprehensive overview of developing PROTACs, from understanding their mechanism to clinical applications, and highlights their emerging role in overcoming drug resistance and advancing the limits of cancer treatment. In addition, the authors discuss the challenges of optimizing PROTACs, including issues related to pharmacokinetics, E3 ligase compatibility, and the delivery of PROTACs to tumors. With their modularity, adaptability, and precision, PROTACs represent a next‐generation platform for personalized cancer therapy across various patient groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Immunology and Microbiology, Medicine, and Oncology Integrated Service Unit, School of Medicine, The University of Texas Rio Grande Valley, McAllen, Texas, USA.
- South Texas Center of Excellence in Cancer Research, School of Medicine, The University of Texas Rio Grande Valley, McAllen, Texas, USA.
- School of Integrative Biological and Chemical Sciences, The University of Texas Rio Grande Valley, Edinburg, Texas, USA.
- School of Earth Environment and Marine Sciences, The University of Texas Rio Grande Valley, Edinburg, Texas, USA.
- Clinical Support Services Integrated Service Unit, School of Medicine, The University of Texas Rio Grande Valley, Edinburg, Texas, USA.
ORCID-Profile: Manish K Tripathi
Förderung
- Alzheimer's Association
- NIH HHS
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Anaya, Y. A., Barragan, M., Bracho, R. P., Shaham, S. H., Bandyopadhyay, D., George, E., Nguyen, D., & Tripathi, M. K. (2025). Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment. Cancer. https://doi.org/10.1002/cncr.70132
Vancouver
Anaya YA, Barragan M, Bracho RP, Shaham SH, Bandyopadhyay D, George E, et al. Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment. Cancer. 2025. doi:10.1002/cncr.70132
BibTeX
@article{Anaya2025,
author = {Anaya, Yamile Abuchard and Barragan, Mariana and Bracho, Ricardo Pequeno and Shaham, Salique H and Bandyopadhyay, Debasish and George, Elias and Nguyen, Diane and Tripathi, Manish K},
title = {Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70132}
}
EUVIMED